Sun Pharma Advanced Research Company Q4 FY26 Results: PAT Rs 1,761 Cr, Revenue Rs 1,853 Crore

Sun Pharma Advanced Research Company Q4 FY26 results were declared on May 18, 2026, at the board of directors meeting. Sun Pharma Advanced Research Company reported PAT of Rs 1,761 crore for the quarter ended March 31, 2026, up 3044.6% YoY from Rs 56 crore in Q4 FY25, on revenue of Rs 1,853 crore. Sun Pharma Advanced Research Company operates in the pharmaceutical research and drug discovery sector. Investors tracking Sun Pharma Advanced Research Company Q4 FY26 will find complete financial analysis and FY27 outlook in this article.

Click Here – Get Free Investment Predictions

Sun Pharma Advanced Research Company Q4 FY26 Financial Highlights

Sun Pharma Advanced Research Company Q4 FY26 Performance Analysis

Sun Pharma Advanced Research Company Q4 FY26 reflects the company’s operational performance during the January to March 2026 quarter. Sun Pharma Advanced Research Company is a leading pharmaceutical research and drug discovery company whose Q4 FY26 print sets the baseline for FY27 guidance. The profitability improvement demonstrates effective operating leverage and cost management. Q4 January to March is typically a seasonally strong quarter for Indian companies driven by year-end government procurement and project completion cycles.

Investors tracking Sun Pharma Advanced Research Company Q4 FY26 will monitor FY27 revenue guidance, margin trajectory, and management commentary. Track Sun Pharma Advanced Research Company on the Univest Screener for live data.

Check the Univest Screener for live data

Key Factors for the company

Revenue and Sector Dynamics

Sun revenue of Rs 1,853 crore reflects the company’s execution in the pharmaceutical research and drug discovery space. India’s sustained economic growth of 6.5%+ and robust domestic demand across sectors provide a supportive backdrop for FY27 business planning.

Profitability and Margin Trends

The company PAT of Rs 1,761 crore up 3044.6% YoY from Rs 56 crore in Q4 FY25 demonstrates consistent earnings delivery and improving profitability metrics. Management commentary on FY27 capex and growth investments will guide the stock’s near-term trajectory.

FY27 Business Outlook

Following the firm results, management guidance on FY27 revenue, order book, and strategic priorities will be key catalysts. Download the Univest iOS App or Univest Android App to receive SEBI-registered analyst research on Sun Pharma Advanced Research Company.

Frequently Asked Questions on Sun

What is the company PAT?

Ans. Sun reported PAT of Rs 1,761 crore up 3044.6% YoY from Rs 56 crore in Q4 FY25. Results declared May 18, 2026. Full details from NSE/BSE regulatory filings. Verify all data before investing.

What is the company revenue?

Ans. The firm’s revenue from operations was Rs 1,853 crore for the quarter ended March 31, 2026. Track live on the Univest Screener.

When were Sun results announced?

Ans. The company results were announced on May 18, 2026, at the board meeting approving audited Q4 and FY26 financial statements for the year ended March 31, 2026.

Is Sun Pharma Advanced Research Company a good investment after Q4 FY26?

Ans. Investment decisions require individual assessment of fundamentals, valuation, sector dynamics, and personal risk tolerance. This article does not constitute investment advice. Consult a SEBI-registered financial advisor before investing.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.